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A Ab bs st tr ra ac ct t
A 100 kb region on 9p21.3 harbors two major disease susceptibility loci: one for type 2 diabetes
(T2D) and one for coronary heart disease (CHD). The single nucleotide polymorphisms (SNPs)
associated with these two diseases in Europeans reside on two adjacent haplotype blocks with
independent effects on disease. To help delimit the regions that likely harbor the disease-causing
variants in populations of non-European origin, we studied the haplotype diversity and allelic
history of the 9p21.3 region using 938 unrelated individuals from 51 populations (Human
Genome Diversity Panel). We used SNP data from Illumina’s 650Y SNP arrays supplemented
with five additional SNPs within the region of interest. Haplotype frequencies were analyzed with
the EM algorithm implemented in PLINK. For the T2D locus, the TT risk haplotype of SNPs
rs10811661 and rs10757283 was present at similar frequencies in all global populations, while a
shared 6-SNP haplotype that carries the protective C allele of rs10811661 was found at a
frequency of 2.9% in Africans and 41.3% in East Asians and was associated with low haplotype
diversity. For the CHD locus, all populations shared a core risk haplotype spanning >17.5 kb,
which shows dramatic increase in frequency between African (11.5%) and Middle Eastern (63.7%)
populations. Interestingly, two SNPs (rs2891168 and rs10757278) tagging this CHD risk
haplotype are most strongly associated with CHD disease status according to independent clinical
fine-mapping studies. The large variation in linkage disequilibrium patterns identified between the
populations demonstrates the importance of allelic background data when selecting SNPs for
replication in global populations. Intriguingly, the protective allele for T2D and the risk allele for
CHD show an increase in frequency in non-Africans compared to Africans, implying different
population histories for these two adjacent disease loci.
F Fi in nd di in ng gs s
A 100 kb region on chromosome 9p21.3 has been recently
identified as harboring susceptibility variants to both
coronary heart disease (CHD)/myocardial infarction [1-5]
and to type 2 diabetes (T2D) [6,7] in study populations of
European origin. The associated variants reside on two
adjacent haplotype blocks, as defined using HapMap data
from 30 trios of Northern and Western European ancestry
(CEU) collected by the Centre d’Etude du Polymorphisme
Humain (CEPH) [8]. The effects of the variants are
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risk of CHD, and vice versa [9,10]. The variants associated
with CHD also contribute to the risk of other disease pheno-
types, such as abdominal aortic and intracranial aneurysms
[10] and ischemic stroke [11]. The extensive linkage
disequilibrium (LD) seen in this genomic region in the CEU
HapMap population is diminished in the other HapMap
populations of African, Chinese and Japanese ancestry, both
for pair-wise LD levels as well as size of the haplotype blocks.
In addition, the disease-associated variants are located in a
genomic region of unknown function. These two issues
contribute to the challenge of identifying the possible
causative variants, and studying their effects in populations
of non-European ancestry.
To help delimit the regions that likely harbor the disease-
causing variants in populations of non-European origin, we
studied the haplotype diversity and allelic history of the
9p21.3 region using existing genotype data from 938 un-
related individuals from 51 populations, from Sub-Saharan
Africa, North Africa, Europe, the Middle East, South/Central
Asia, East Asia, Oceania and the Americas (the Human
Genome Diversity Panel (HGDP-CEPH) [12]). Descriptions
of genome-wide single nucleotide polymorphism (SNP)
variation across these populations have recently been
published by two independent groups, using Illumina’s
HumanHap550 BeadChip in 29 populations [13] and
HumanHap650Y BeadChip in 51 populations [14]. Here we
present an analysis of the 650Y SNP data [14], supplemented
with five additional SNPs: rs11790231, rs10965227,
rs7045889 and rs10811661 typed using Sequenom iPLEX
chemistry (Sequenom, San Diego, CA, USA) and rs1333049
typed using KASPar chemistry (Kbioscience, Hoddesdon,
Herts, UK) [15]. The additional SNPs were selected to
include disease-associated SNPs and haplotype-tagging
SNPs that were not present on the 650Y chip. Genotype
quality controls included eight duplicates of a CEPH sample
and eight water controls in every 384-well plate. Genotype
clusters were manually reviewed and genotyping success
rate for each SNP was >98.9%. The genotype data included
the variants associated with T2D (rs10811661 and
rs10757283), as well as eight variants associated with CHD
or found in high LD (r2 > 0.9) with associated variants
across a 44 kb region (rs10116277, rs1537370, rs10738607,
rs4977574, rs944797, rs2383207, rs1537375 and rs1333049)
in the HapMap CEU population. Haplotype frequencies were
analyzed with the EM algorithm implemented in PLINK
[16], which estimates the frequencies of probabilistically
inferred sets of haplotypes within a population-based
sample set. Haplotype structure was visualized with Haplo-
view [17]. The analysis was performed for each geographic
region separately, including in the analysis all individuals
from the various populations in that geographic region. Due
to the small number of unrelated individuals studied here
and the uncertainty of phasing, we omit region-specific
haplotypes with frequencies <5%.
Our analyses show that the T2D and CHD loci have different
allelic histories, which is in agreement with their indepen-
dent effects on disease. The haplotype structure of the
critical region containing the CHD- and T2D-associated
SNPs in the HGDP European sample is shown in Figure 1,
and for comparison the same region is shown in the HGDP
African sample (Additional data file 1). For the T2D locus,
the T allele of rs10811661 was found to be associated with
disease risk [6], while a larger meta-analysis identified
haplotype TT of rs10811661 and rs10757283 as most strongly
associated with disease [7]. The TT risk haplotype is present
in similar frequencies in all global populations, while a
shared 6-SNP haplotype that carries the protective C allele of
rs10811661 is found at a frequency of 2.9% in Africans and
41.3% in East Asians and is associated with low haplotype
diversity (Table 1). This frequency difference between
populations and lack of haplotype diversity of the protective
allele is reminiscent of the TCF7L2 T2D locus, in which the
protective allele is found at a frequency of 10 to 31% in
Africans but at 95% in East Asians [15,18]. Such large allele
frequency differences and lack of haplotype diversity are
indications of the past action of positive natural selection
[19]. However, the degree of population differentiation for
rs10811661 is not unusual compared to random SNPs in the
genome (Fst = 0.126 (P = 0.224) across the 51 HGDP popu-
lations) [15], suggesting a neutrally selected region, while the
protective allele of rs7901695 at the TCF7L2 locus was likely
driven to high frequency in East Asians (global Fst = 0.213
(P = 0.08) across the 51 HGDP populations) by positive
selection [18].
The risk allele frequencies of four of the CHD-associated
SNPs are shown in Figure 2. Although these SNPs show
highly similar allele frequencies and are in almost perfect LD
in European populations (r2 > 0.9), they show dramatic
differences in allele frequencies across other populations,
most notably in African populations. In order to decipher
which of these risk alleles might be the true causative variant
(or in high LD with it) and thus may be suitable for testing in
non-European populations, we studied the haplotype diver-
sity across the different geographic regions for eight highly
correlated CHD-associated SNPs (r2 > 0.9 in CEU HapMap
population; Table 2). All populations appear to share a core
risk haplotype as a part of the longer risk haplotype identi-
fied in Europeans. This risk haplotype (GGGC, for SNPs
rs4977574, rs944797, rs2383207, rs1537375) spans >17.5 kb,
and is tagged by the risk allele G of SNP rs4977574. The G
allele of rs4977574 is also the best tag SNP for the longer risk
haplotype (>44.1 kb) that is most common in all popula-
tions. All the other CHD-associated risk alleles were also
found on other haplotypes in non-European populations.
The risk allele of rs4977574 shows a dramatic change in
frequency between African and Middle Eastern populations
(Figure 2), and tags the only 8-SNP haplotype of African
origin that becomes common in European populations
(Table 2). Interestingly, two comprehensive fine-mapping
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F Fi ig gu ur re e   1 1
The pattern of LD in the European HGDP samples on chromosome 9:22071397-22124172, a region approximately 53 kb long. R2 values between each
SNP pair are shown in shades of grey (black R2 = 1, white R2 = 0) and within each box. The CHD and T2D LD regions in Europeans are clearly separate.
The SNPs best tagging the disease-associating haplotypes (rs4977574 and rs10811661) are in bold- face. The positions of two SNPs that have been
identified as most strongly associated with CHD in two separate fine-mapping studies of Europeans, rs2891168 and rs10757278 (see text), are shown











































































































































































































T Ta ab bl le e   1 1
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Middle C.S.  E.
Africa East  Europe  Asia Asia  Oceania  America 
rs2383208 rs7045889 rs10811659 rs10757282 rs10811661 rs10757283 N=102 N=160 N=156 N=200 N=229 N=28 N=63
G G A A A A G G C C T T 0.029 0.197 0.157 0.125 0.393 0.446 0.167
AAAGT T* * T T* * 0.118 0.187 0.266 0.221 0.215 0.196 0.206
GGAAT T* * T T* * 0.131 0.022 NF NF NF NF NF
AAAAT T* * T T* * 0.182 NF NF NF NF NF NF
GAAAT T* * T T* * 0.052 NF NF NF NF NF NF
A G A A T C 0.302 0.334 0.308 0.418 0.244 0.089 0.547
A A G A T C 0.022 0.177 0.198 0.199 0.091 0.161 NF
A G G A T C 0.051 0.038 0.046 0.018 0.011 0.071 0.024
G G A A T C 0.042 0.015 NF NF NF NF NF
A A A A T C 0.053 NF NF NF NF NF 0.024
The TT haplotype of SNPs rs10811661 and rs10757283 is the T2D risk haplotype and is in bold-face and marked with an asterisk, while the protective
haplotype (GAAGCT) is in bold-face and italicized. †Population-specific haplotypes <5% frequent were omitted. NF, haplotype not found in given
geographic region.http://genomemedicine.com/content/1/5/51 Genome Medicine 2009, Volume 1, Issue 5, Article 51 Silander et al. 51.4
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F Fi ig gu ur re e   2 2
Risk allele frequencies across 51 populations for four CHD-associated SNPs that are highly correlated in European populations. The number of
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Risk allele frequencystudies of this region in case-control samples have identified
SNPs in the same haplotype block as rs4977574 (rs2891168
and rs10757278, shown in Figure 1) as most strongly
associated with disease [1,9]. These three SNPs (rs4977574,
rs2891168, and rs10757278) are highly correlated with each
other in all four HapMap populations and are the most
appropriate for further analyses in non-Europeans. The 44
kb LD region harbors the ANRIL (antisense noncoding RNA
in the INK4 locus) gene, which codes for a large antisense
non-coding RNA, and was found to be expressed in tissues
involved in atherosclerosis [9]. The three CHD risk
haplotype tagging SNPs are located in regions of regulatory
potential, as defined from alignments of several mammalian
sequences [20,21], and thus may be representing the actual
functional domains associated with disease risk.
A handful of replication studies in non-European popula-
tions for CHD-related phenotypes have been published to
date. Most of these studies make use of populations of East
Asian ancestry [22-25] in which patterns of LD are similar to
LD patterns in Europeans. Not surprisingly, these studies
confirm previously described associations with disease
phenotypes discovered in populations of European ancestry.
A replication study in a multi-ethnic sample [26] that
included relatively small numbers of cases and controls per
ethnic origin confirmed association in Hispanics, but found
no association in African Americans, possibly due to the
small sample size and the low frequency of the alleles
studied. Studies from populations of diverse ancestry are
generally lacking. Our results demonstrate the importance of
ancestry-specific allelic background when selecting SNPs for
replication in global populations, and demonstrate that this
approach can complement fine-mapping studies to possibly
identify novel putative causative variant/s. Intriguingly, our
data imply very different population histories for these two
adjacent disease loci, with an increase in the prevalence of
the T2D protective allele, most notably in East Asian
populations, versus an increase in the prevalence of the CHD
risk allele already in Middle Eastern populations. The HGDP
SNP data we used here are publicly available and represent a
valuable resource for studies of other complex diseases.
A Ab bb br re ev vi ia at ti io on ns s
CEPH, Centre d’Etude du Polymorphisme Humain; CEU,
HapMap data from 30 trios of Northern and Western
European ancestry; CHD, coronary heart disease; HGDP,
Human Genome Diversity Panel; LD, linkage disequilibrium;
SNP, single nucleotide polymorphism; T2D, type 2 diabetes.
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Middle C.S. E.
Africa East Europe Asia  Asia Oceania  America 
rs10116277 rs1537370 rs10738607 rs4977574 rs944797 rs2383207 rs1537375 rs1333049 N=102 N=160 N=156 N=200 N=229 N=28 N=63
G C T A A A T G NF 0.209 0.384 0.327 0.328 0.554 0.449
T T T T C C G G* * G G* * G G* * C C* * C C 0.115 0.516 0.536 0.478 0.470 0.161 0.302
T T T T C C G G* * G G* * G G* * C C* * G NF 0.100 0.031 0.029 NF 0.143 NF
GC C C G G* * G G* * G G* * C C* * C C NF 0.021 0.017 NF 0.019 NF 0.032
T T T T C C A G G G G C C G 0.021 0.019 NF NF NF NF NF
T T T T TA A G G C C G 0.345 0.041 NF NF NF 0.054 NF
T T CTA A G G C C G 0.246 0.013 NF NF NF NF 0.016
T T T T C C AAG G C C G NF NF NF 0,035 0.092 0.054 NF
T T T T TA G G G G T G 0.129 0.031 NF 0,027 NF NF NF
GC T A G G G G C C C C NF NF NF NF NF NF 0.147
GC T A A G G C C G 0.027 NF NF NF NF 0.036 NF
T T T T T A A A T G NF 0.019 NF 0,015 0.039 NF 0.012
GC T A A A T C C NF NF NF 0,013 NF NF 0.016
The risk alleles in Europeans are in bold-face and italicized, and the core risk haplotype is marked with an asterisk. †Population-specific haplotypes <5%
frequent were omitted. NF, haplotype not found in given geographic region.involved in the statistical analyses of the data. All authors
participated in discussing study design and results inter-
pretation, and read, commented and approved the final
manuscript.
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The following additional data are available with the online
version of this paper. Additional data file 1 is a Powerpoint
file showing the pattern of linkage disequilibrium in the
African HGDP samples on chromosome 9:22071397-
22124172, a region approximately 53 kb long.
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